SCHEMBL4712475

SCHEMBL4712475

Cc1cccc(C=Cc2cc(Cl)cc(Cl)c2Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.49
KMT2A Q03164 8/20 0.49
RAB9A P51151 5/20 0.49
NPC1 O15118 5/20 0.49
ALDH1A1 P00352 3/20 0.49
GRM5 P41594 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
HPGD P15428 2/20 0.49
GRM4 Q14833 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
PKM P14618 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49
CYP2C19 P33261 1/20 0.49
THPO P40225 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4712472 1.00 MEN1 (0.49) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4712450 0.83 KMT2A (0.53) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4712448 0.83 KMT2A (0.53) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4713161 0.78 MEN1 (0.67) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4713163 0.78 MEN1 (0.67) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4713818 0.78 ALDH1A1 (0.64) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4713819 0.78 ALDH1A1 (0.64) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4761687 0.78 KMT2A (0.59) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4761685 0.78 KMT2A (0.59) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4712658 0.76 RAB9A (0.76) MEN1KMT2ARAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP claimed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed